{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:40:07Z","timestamp":1788478807967,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Enterotoxin-based adjuvants including cholera toxin and heat-labile toxin (LT) are powerful manipulators of mucosal immunity; however, past clinical trials identified unacceptable neurological toxicity when LT or mutant AB<jats:sub>5<\/jats:sub>adjuvant proteins were added to intranasal vaccines. Here, we examined the isolated enzymatic A1 domain of LT (LTA1) for intranasal safety and efficacy in combination with influenza (flu) vaccination. LTA1-treated mice exhibited no neurotoxicity, as measured by olfactory system testing and H&amp;E staining of nasal tissue in contrast with cholera toxin. In vaccination studies, intranasal LTA1 enhanced immune responses to inactivated virus antigen and subsequent protection against H1N1 flu challenge in mice (8-week or 24-months). In addition, lung H1N1 viral titers post-challenge correlated to serum antibody responses; however, enhanced protection was also observed in \u03bcMT mice lacking B-cells while activation and recruitment of CD4 T-cells into the lung was apparent. Thus, we report that LTA1 protein is a novel, safe and effective enterotoxin adjuvant that improves protection of an intranasal flu vaccination by a mechanism that does not appear to require B-cells.<\/jats:p>","DOI":"10.1038\/s41598-019-51356-w","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:26:13Z","timestamp":1571804773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (\u03bcMT) mice"],"prefix":"10.1038","volume":"9","author":[{"given":"E.","family":"Valli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-1592","authenticated-orcid":false,"given":"A. J.","family":"Harriett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Nowakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Baudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. B.","family":"Provosty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"McSween","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. B.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. B.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"51356_CR1","unstructured":"Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006\u20132015. MMWR Morb Mortal Wkly Rep 55, 511\u2013515 (2006)."},{"key":"51356_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.1314688110","volume":"111","author":"JM Warfel","year":"2014","unstructured":"Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 111, 787\u2013792 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"51356_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.coi.2015.05.008","volume":"35","author":"JM Warfel","year":"2015","unstructured":"Warfel, J. M. & Edwards, K. M. Pertussis vaccines and the challenge of inducing durable immunity. Curr Opin Immunol 35, 48\u201354 (2015).","journal-title":"Curr Opin Immunol"},{"key":"51356_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","volume":"16","author":"PF Wright","year":"2016","unstructured":"Wright, P. F. et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis 16, 1377\u20131384 (2016).","journal-title":"Lancet Infect Dis"},{"key":"51356_CR5","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.4049\/jimmunol.162.8.5011","volume":"162","author":"TM Herremans","year":"1999","unstructured":"Herremans, T. M., Reimerink, J. H., Buisman, A. M., Kimman, T. G. & Koopmans, M. P. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 162, 5011\u20135018 (1999).","journal-title":"J Immunol"},{"key":"51356_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fimmu.2016.00041","volume":"7","author":"JE McElhaney","year":"2016","unstructured":"McElhaney, J. E., Kuchel, G. A., Zhou, X., Swain, S. L. & Haynes, L. T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines. Front Immunol 7, 41 (2016).","journal-title":"Front Immunol"},{"key":"51356_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0140-6736(05)70806-0","volume":"365","author":"J Ruxin","year":"2005","unstructured":"Ruxin, J. et al. Emerging consensus in HIV\/AIDS, malaria, tuberculosis, and access to essential medicines. Lancet 365, 618\u2013621 (2005).","journal-title":"Lancet"},{"key":"51356_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1128\/CMR.14.2.430-445.2001","volume":"14","author":"PL Ogra","year":"2001","unstructured":"Ogra, P. L., Faden, H. & Welliver, R. C. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14, 430\u2013445 (2001).","journal-title":"Clin Microbiol Rev"},{"key":"51356_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s13346-012-0085-z","volume":"3","author":"M Zaman","year":"2013","unstructured":"Zaman, M., Chandrudu, S. & Toth, I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 3, 100\u2013109 (2013).","journal-title":"Drug Deliv Transl Res"},{"key":"51356_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jps.21493","volume":"98","author":"S Sharma","year":"2009","unstructured":"Sharma, S., Mukkur, T. K., Benson, H. A. & Chen, Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 98, 812\u2013843 (2009).","journal-title":"J Pharm Sci"},{"key":"51356_CR11","doi-asserted-by":"crossref","unstructured":"Clements, J. D. & Norton, E. B. The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT. mSphere 3 (2018).","DOI":"10.1128\/mSphere.00215-18"},{"key":"51356_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0264-410X(88)90223-X","volume":"6","author":"JD Clements","year":"1988","unstructured":"Clements, J. D., Hartzog, N. M. & Lyon, F. L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6, 269\u2013277 (1988).","journal-title":"Vaccine"},{"key":"51356_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1128\/CVI.00538-10","volume":"18","author":"EB Norton","year":"2011","unstructured":"Norton, E. B., Lawson, L. B., Freytag, L. C. & Clements, J. D. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 18, 546\u2013551 (2011).","journal-title":"Clin Vaccine Immunol"},{"key":"51356_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","volume":"350","author":"M Mutsch","year":"2004","unstructured":"Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland. N Engl J Med 350, 896\u2013903 (2004).","journal-title":"N Engl J Med"},{"key":"51356_CR15","doi-asserted-by":"publisher","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","volume":"4","author":"DJ Lewis","year":"2009","unstructured":"Lewis, D. J. et al. Transient facial nerve paralysis (Bell\u2019s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4, e6999 (2009).","journal-title":"PLoS One"},{"key":"51356_CR16","doi-asserted-by":"crossref","first-page":"12861","DOI":"10.1016\/S0021-9258(18)42975-4","volume":"256","author":"J Moss","year":"1981","unstructured":"Moss, J., Osborne, J. C. J., Fishman, P. H., Nakaya, S. & Robertson, D. C. Escherichia coli heat-labile enterotoxin. Ganglioside specificity and ADP-ribosyltransferase activity. J Biol Chem 256, 12861\u201312865 (1981).","journal-title":"J Biol Chem"},{"key":"51356_CR17","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.4049\/jimmunol.0803992","volume":"183","author":"L Fahlen-Yrlid","year":"2009","unstructured":"Fahlen-Yrlid, L. et al. CD11c(high)dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization. J Immunol 183, 5032\u20135041 (2009).","journal-title":"J Immunol"},{"key":"51356_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mi.2007.7","volume":"1","author":"NG Anosova","year":"2008","unstructured":"Anosova, N. G. et al. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer\u2019s patches. Mucosal Immunol 1, 59\u201367 (2008).","journal-title":"Mucosal Immunol"},{"key":"51356_CR19","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.4049\/jimmunol.1003789","volume":"186","author":"CF Brereton","year":"2011","unstructured":"Brereton, C. F. et al. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol 186, 5896\u20135906 (2011).","journal-title":"J Immunol"},{"key":"51356_CR20","doi-asserted-by":"publisher","first-page":"e51718","DOI":"10.1371\/journal.pone.0051718","volume":"7","author":"S Leach","year":"2012","unstructured":"Leach, S., Clements, J. D., Kaim, J. & Lundgren, A. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS One 7, e51718 (2012).","journal-title":"PLoS One"},{"key":"51356_CR21","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.4049\/jimmunol.1401633","volume":"194","author":"M Larena","year":"2015","unstructured":"Larena, M., Holmgren, J., Lebens, M., Terrinoni, M. & Lundgren, A. Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling. Journal of immunology 194, 3829\u20133839 (2015).","journal-title":"Journal of immunology"},{"key":"51356_CR22","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1128\/IAI.73.10.6892-6902.2005","volume":"73","author":"FW van Ginkel","year":"2005","unstructured":"van Ginkel, F. W. et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 73, 6892\u20136902 (2005).","journal-title":"Infect Immun"},{"key":"51356_CR23","doi-asserted-by":"publisher","first-page":"e0139368","DOI":"10.1371\/journal.pone.0139368","volume":"10","author":"Y Fukuyama","year":"2015","unstructured":"Fukuyama, Y. et al. Nasal Administration of Cholera Toxin as a Mucosal Adjuvant Damages the Olfactory System in Mice. PLoS One 10, e0139368 (2015).","journal-title":"PLoS One"},{"key":"51356_CR24","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1128\/IAI.00181-12","volume":"80","author":"EB Norton","year":"2012","unstructured":"Norton, E. B., Lawson, L. B., Mahdi, Z., Freytag, L. C. & Clements, J. D. The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun 80, 2426\u20132435 (2012).","journal-title":"Infect Immun"},{"key":"51356_CR25","doi-asserted-by":"publisher","first-page":"e0136302","DOI":"10.1371\/journal.pone.0136302","volume":"10","author":"EB Norton","year":"2015","unstructured":"Norton, E. B., Branco, L. M. & Clements, J. D. Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). PLoS One 10, e0136302 (2015).","journal-title":"PLoS One"},{"key":"51356_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1586\/14760584.2.2.295","volume":"2","author":"R Zurbriggen","year":"2003","unstructured":"Zurbriggen, R., Metcalfe, I. C., Gluck, R., Viret, J. F. & Moser, C. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert review of vaccines 2, 295\u2013304 (2003).","journal-title":"Expert review of vaccines"},{"key":"51356_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1078\/0940-2993-00349","volume":"55","author":"B Kittel","year":"2004","unstructured":"Kittel, B. et al. Revised guides for organ sampling and trimming in rats and mice\u2013Part 2. A joint publication of the RITA and NACAD groups. Exp Toxicol Pathol 55, 413\u2013431 (2004).","journal-title":"Exp Toxicol Pathol"},{"key":"51356_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12931-017-0708-5","volume":"19","author":"ES Halstead","year":"2018","unstructured":"Halstead, E. S. et al. GM-CSF overexpression after influenza a virus infection prevents mortality and moderates M1-like airway monocyte\/macrophage polarization. Respir Res 19, 3 (2018).","journal-title":"Respir Res"},{"key":"51356_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/mi.2012.2","volume":"5","author":"O Dienz","year":"2012","unstructured":"Dienz, O. et al. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol 5, 258\u2013266 (2012).","journal-title":"Mucosal Immunol"},{"key":"51356_CR30","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.vaccine.2009.01.136","volume":"27","author":"JE McElhaney","year":"2009","unstructured":"McElhaney, J. E. et al. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 27, 2418\u20132425 (2009).","journal-title":"Vaccine"},{"key":"51356_CR31","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1084\/jem.186.12.2063","volume":"186","author":"MB Graham","year":"1997","unstructured":"Graham, M. B. & Braciale, T. J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186, 2063\u20132068 (1997).","journal-title":"J Exp Med"},{"key":"51356_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1086\/599790","volume":"200","author":"AR Falsey","year":"2009","unstructured":"Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J. & Gorse, G. J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 200, 172\u2013180 (2009).","journal-title":"J Infect Dis"},{"key":"51356_CR33","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ajpath.2012.12.007","volume":"182","author":"DA Pociask","year":"2013","unstructured":"Pociask, D. A. et al. IL-22 is essential for lung epithelial repair following influenza infection. Am J Pathol 182, 1286\u20131296 (2013).","journal-title":"Am J Pathol"},{"key":"51356_CR34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1146\/annurev-immunol-032414-112123","volume":"33","author":"JA Dudakov","year":"2015","unstructured":"Dudakov, J. A., Hanash, A. M. & van den Brink, M. R. Interleukin-22: immunobiology and pathology. Annu Rev Immunol 33, 747\u2013785 (2015).","journal-title":"Annu Rev Immunol"},{"key":"51356_CR35","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1128\/IAI.69.3.1528-1535.2001","volume":"69","author":"CC Bowman","year":"2001","unstructured":"Bowman, C. C. & Clements, J. D. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect Immun 69, 1528\u20131535 (2001).","journal-title":"Infect Immun"},{"key":"51356_CR36","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1046\/j.1440-1711.1998.00750.x","volume":"76","author":"L Agren","year":"1998","unstructured":"Agren, L., Lowenadler, B. & Lycke, N. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol Cell Biol 76, 280\u2013287 (1998).","journal-title":"Immunol Cell Biol"},{"key":"51356_CR37","doi-asserted-by":"crossref","unstructured":"Cox, N. J., Trock, S. C. & Burke, S. A. Pandemic Preparedness and the Influenza Risk Assessment Tool (IRAT). Current topics in microbiology and immunology (2014).","DOI":"10.1007\/82_2014_419"},{"key":"51356_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1586\/14760584.3.1.35","volume":"3","author":"HG Stiver","year":"2004","unstructured":"Stiver, H. G. The threat and prospects for control of an influenza pandemic. Expert review of vaccines 3, 35\u201342 (2004).","journal-title":"Expert review of vaccines"},{"key":"51356_CR39","first-page":"1057","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza\u2013United States, 1976\u20132007. MMWR Morbidity and mortality weekly report 59, 1057\u20131062 (2010).","journal-title":"MMWR Morbidity and mortality weekly report"},{"key":"51356_CR40","doi-asserted-by":"crossref","unstructured":"Del Giudice, G. & Rappuoli, R. Inactivated and Adjuvanted Influenza Vaccines. Current topics in microbiology and immunology (2014).","DOI":"10.1007\/82_2014_406"},{"key":"51356_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/pr.2017.239","volume":"83","author":"MA Gill","year":"2018","unstructured":"Gill, M. A. & Schlaudecker, E. P. Perspectives from the Society for Pediatric Research: Decreased Effectiveness of the Live Attenuated Influenza Vaccine. Pediatr Res 83, 31\u201340 (2018).","journal-title":"Pediatr Res"},{"key":"51356_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/350423a0","volume":"350","author":"D Kitamura","year":"1991","unstructured":"Kitamura, D., Roes, J., Kuhn, R. & Rajewsky, K. A. B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350, 423\u2013426 (1991).","journal-title":"Nature"},{"key":"51356_CR43","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1128\/JVI.01805-09","volume":"84","author":"EB Norton","year":"2010","unstructured":"Norton, E. B., Clements, J. D., Voss, T. G. & Cardenas-Freytag, L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol 84, 2983\u20132995 (2010).","journal-title":"J Virol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51356-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51356-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51356-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T23:52:15Z","timestamp":1695340335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51356-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51356"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51356-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15128"}}